drugset / Trial / NCT05720949

Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery

NCT05720949 ↗

Phase 4 Completed 192 enrolled Hospital for Special Surgery, New York
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this randomized controlled trial is to assess a new analgesia regimen that includes the addition of genicular never blocks to our current standard regimen of peripheral nerve blocks, which includes an adductor canal block (ACB) and interspace between the popliteal artery and capsule of the posterior knee block (IPACK). The main questions it aims to answer are: 1. Does addition of genicular nerve blocks to standard peripheral block regimen significantly reduce the mean opioid consumption by 33% in the first 24 hours? 2. Does genicular nerve blocks reduce NRS pain scores? 3. Does genicular nerve blocks facilitate earlier discharge? 4. Does genicular nerve blocks last longer than 24 hours? 5. Does genicular nerve blocks improve pain management? Eligible patients are those undergoing an anterior cruciate ligament repair at the Hospital for Special Surgery and participants will be randomized to receive the intervention (genicular nerve block) or the standard of care.

Timeline

Start
2023-01-12
Primary completion
2024-11-26
Completion
2024-12-02

Outcome

Missed primary endpoint

registry analysis (superiority test); Group 1 - Control vs Group 2 - Intervention; p = 0.17; Wilcoxon (Mann-Whitney) NCT05720949 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.25 % —
Subject Dexamethasone Small molecule 2 mg —

Indications

No indication recorded.